Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy

NCT02515942 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT02515942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02515942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy
Lead sponsor
Alcon Research
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2015
Completion date
December 1, 2017
Enrollment
114 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy